About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals is a private company based in Malvern, Pennsylvania. It has reported $124,255,070 raised in five offerings on Form D since December 2013.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2023 | Feb 27, 2023amended Jul 13, 2023 | $35,008,357of $48.2M target | 3 | $11.6M | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Aug 19, 2022 | Sep 2, 2022amended Dec 22, 2022 | $24,700,001fully sold | 2 | $12.3M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 18, 2022 | Apr 4, 2022 | $34,000,000of $59.9M target | 3 | $11.3M | EquityRule 506(b) | Form D ↗ |
| Jul 13, 2017 | Jul 25, 2017amended Nov 5, 2018 | $27,127,661of $47.1M target | 47 | $577K | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Nov 22, 2013 | Dec 4, 2013 | $3,419,051of $3.9M target | 59 | $57,950 | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $124,255,070 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Venatorx Pharmaceuticals's Form D filed Jul 13, 2023.
Earlier filings also listed Timothy Henkel (executive officer, last listed Dec 2022), Michael Diem (director, last listed Dec 2022), Ezra Felker (executive officer, last listed Dec 2022), Vincent Milano (director, last listed Apr 2022), Shelley Chu (director, last listed Nov 2018), Carlo Rizzuto (director, last listed Nov 2018) and Luigi Xerri (executive officer and director, last listed Dec 2013).